Cabergoline, a selective dopamine D2-receptor agonist dopamine receptor agonist, has been shown in clinical trials to inhibit vascular endothelial growth factor and prevent angiogenesis in the progression of endometriosis, thereby shrinking endometriosis lesions (52). This evidence concerns the gene DRD2 and endometriosis.